Trials / Completed
CompletedNCT03402828
Body PSOriasis: Long-term Relapse CONTROL
Body PSOriasis: Long-term Relapse Control in Patients With Psoriasis Vulgaris in Daily Clinical Practice of Russian Dermatologists.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 764 (actual)
- Sponsor
- LEO Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This non-interventional study of real-life clinical practice strategies for long-term relapse control in patients with psoriasis vulgaris is planned to enroll 650 adult patients from 60-100 Russian dermatology sites and follow the patients for up to 52 weeks. The study will map actual strategies and focus on patients' and dermatologists' experience with the different topicals used, including unspecified products with and without active drugs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Any topical drug treatment | Any treatment strategy used to prevent relapse of psoriasis symptoms |
Timeline
- Start date
- 2018-06-11
- Primary completion
- 2020-05-15
- Completion
- 2020-05-15
- First posted
- 2018-01-18
- Last updated
- 2021-03-16
Locations
1 site across 1 country: Russia
Source: ClinicalTrials.gov record NCT03402828. Inclusion in this directory is not an endorsement.